OOIR: Observatory of International Research

Papers

(The TQCC of Clinical and Molecular Hepatology is 10. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma	251
KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease	176
Global incidence and prevalence of nonalcoholic fatty liver disease	157
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma	128
MAFLD: How is it different from NAFLD?	128
Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach	100
Obesity and the risk of primary liver cancer: A systematic review and meta-analysis	94
The development of mesenchymal stem cell therapy in the present, and the perspective of cell-free therapy in the future	85
Recent updates on the management of autoimmune hepatitis	81
Current understanding of primary biliary cholangitis	78
<i>Lactobacillus</i> attenuates progression of nonalcoholic fatty liver disease by lowering cholesterol and steatosis	74
From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?	66
MAFLD enhances clinical practice for liver disease in the Asia-Pacific region	64
Non-alcoholic fatty liver disease: Definition and subtypes	60
Non-alcoholic fatty liver disease increases risk of carotid atherosclerosis and ischemic stroke: An updated meta-analysis with 135,602 individuals	60
Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis	57
KASL clinical practice guidelines for management of chronic hepatitis B	56
The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease	54
Recent advances in nonalcoholic fatty liver disease metabolomics	50
The effect of diabetes and prediabetes on the prevalence, complications and mortality in nonalcoholic fatty liver disease	50
RNA interference as a novel treatment strategy for chronic hepatitis B infection	44
Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name	44
Changes in the epidemiology and management of bacterial infections in cirrhosis	42
Optimizing the management of intermediate-stage hepatocellular carcinoma: Current trends and prospects	40
Updates in the quantitative assessment of liver fibrosis for nonalcoholic fatty liver disease: Histological perspective	40

Outcomes after liver transplantation in Korea: Incidence and risk factors from Korean transplantation registry	38
The management of post-transplantation recurrence of hepatocellular carcinoma	36
The latest global burden of liver cancer: A past and present threat	36
Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Chinese perspective	34
COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis	33
Scaling up the in-hospital hepatitis C virus care cascade in Taiwan	32
Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity	32
Evaluation and management of extrahepatic manifestations of nonalcoholic fatty liver disease	32
Impact of diabetes, obesity, and dyslipidemia on the risk of hepatocellular carcinoma in patients with chronic liver diseases	32
Causes and risk profiles of mortality among individuals with nonalcoholic fatty liver disease	32
Toward a complete cure for chronic hepatitis B: Novel therapeutic targets for hepatitis B virus	32
Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma	31
Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region	29
Anti-fibrotic treatments for chronic liver diseases: The present and the future	29
β-blockers in advanced cirrhosis: More friend than enemy	28
Hepatocellular carcinoma statistics in South Korea	28
Interaction between sarcopenia and nonalcoholic fatty liver disease	27
Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: Challenges and perspectives	27
Three heads are better than two: Hepatitis B core-related antigen as a new predictor of hepatitis B virus-related hepatocellular carcinoma	26
Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients: A propensity score-matched analysis	26
Surgery versus radiofrequency ablation in patients with Child- Pugh class-A/single small (≤3 cm) hepatocellular carcinoma	26
Crosstalk between tumor-associated macrophages and neighboring cells in hepatocellular carcinoma	26
Association of non-alcoholic fatty liver disease with incident dementia later in life among elder adults	25
Risk factors in nonalcoholic fatty liver disease	25
Persistence of intrahepatic hepatitis B virus DNA integration in patients developing hepatocellular carcinoma after hepatitis B surface antigen seroclearance	24
Baveno-VII criteria to predict decompensation and initiate non-selective beta-blocker in compensated advanced chronic liver disease patients	24
Overview of Asian clinical practice guidelines for the management of hepatocellular carcinoma: An Asian perspective comparison	24
Impact of fatty liver on long-term outcomes in chronic hepatitis B: a systematic review and matched analysis of individual patient data meta-analysis	23
Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B	23
Radiation-induced abscopal effect and its enhancement by programmed cell death 1 blockade in the hepatocellular carcinoma: A murine model study	23
Global burden of primary liver cancer and its association with underlying aetiologies, sociodemographic status, and sex differences from 1990–2019: A DALY-based analysis of the Global Burden of Diseas	23
Loss-of-function HSD17B13 variants, non-alcoholic steatohepatitis and adverse liver outcomes: Results from a multi-ethnic Asian cohort	22
Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF- κB signaling pathways	22
Hepatocellular carcinoma incidence is decreasing in Korea but increasing in the very elderly	22
Comparison between obese and non-obese nonalcoholic fatty liver disease	21
Impact of nationwide hepatocellular carcinoma surveillance on the prognosis in patients with chronic liver disease	21
Development of hepatocellular carcinoma in treated and untreated patients with chronic hepatitis B virus infection	21
The best predictive model for hepatocellular carcinoma in patients with chronic hepatitis B infection	21
Development and prognosis of hepatocellular carcinoma in patients with diabetes	20
Gut-derived lipopolysaccharide promotes alcoholic hepatosteatosis and subsequent hepatocellular carcinoma by stimulating neutrophil extracellular traps through toll-like receptor 4	20
Waiting for the changes after the adoption of steatotic liver disease	20
Impact of everolimus on survival after liver transplantation for hepatocellular carcinoma	20
The role of transjugular intrahepatic portosystemic shunt in patients with portal hypertension: Advantages and pitfalls	19
Noninvasive serum biomarkers for liver fibrosis in NAFLD: current and future	19
Acute-on-chronic liver failure: Terminology, mechanisms and management	19
The usefulness of metabolic score for insulin resistance for the prediction of incident non-alcoholic fatty liver disease in Korean adults	19
Noninvasive imaging biomarkers for liver fibrosis in nonalcoholic fatty liver disease: current and future	19
Imaging diagnosis of hepatocellular carcinoma: Future directions with special emphasis on hepatobiliary magnetic resonance imaging and contrast-enhanced ultrasound	19
New next-generation microwave thermosphere ablation for small hepatocellular carcinoma	18
Intrahepatic cholangiocarcinoma: Tumour heterogeneity and its clinical relevance	18

Screening strategy for non-alcoholic fatty liver disease	18
Acute hepatitis C virus infection: clinical update and remaining challenges	17
Liver transplantation for non-alcoholic fatty liver disease: indications and post-transplant management	17
Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase	16
U-shaped relationship between urea level and hepatic decompensation in chronic liver diseases	16
Prevalence trends of non-alcoholic fatty liver disease among young men in Korea: A Korean military population-based cross-sectional study	16
Serum lipocalin-2 is a potential biomarker for the clinical diagnosis of nonalcoholic steatohepatitis	16
Wnt signaling in liver regeneration, disease, and cancer	16
Alcohol associated liver cirrhotics have higher mortality after index hospitalization: Long-term data of 5,138 patients	16
Current and future strategies for the treatment of chronic hepatitis C	15
Systematic review with meta-analysis: Non-alcoholic fatty liver disease and the association with pregnancy outcomes	15
Association of Visceral Fat Obesity, Sarcopenia, and Myosteatosis with Non-Alcoholic Fatty Liver Disease without Obesity	15
Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases	15
Association between serum tumor necrosis factor-α and sarcopenia in liver cirrhosis	14
Prediction models of hepatocellular carcinoma recurrence after liver transplantation: A comprehensive review	14
Approaches to quantifying hepatitis B virus covalently closed circular DNA	14
Genetics in non-alcoholic fatty liver disease: The role of risk alleles through the lens of immune response	14
History and future of hepatitis B virus control in South Korea	14
Metabolic disease as a risk of hepatocellular carcinoma	14
A cost-effectiveness study of universal screening for hepatitis C virus infection in South Korea: A societal perspective	14
Serum fibrosis index-based risk score predicts hepatocellular carcinoma in untreated patients with chronic hepatitis B	14
Management of refractory ascites	14
Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: A narrative review	14
Nonalcoholic fatty liver disease and non-liver comorbidities	13
Impacts of muscle mass dynamics on prognosis of outpatients with cirrhosis	13
The emerging roles of extracellular vesicles as intercellular messengers in liver physiology and pathology	13
Cause of death and cause-specific mortality for primary liver cancer in South Korea: A nationwide population-based study in hepatitis B virus-endemic area	13
Effect of moderate-to-severe hepatic steatosis on neutralising antibody response among BNT162b2 and CoronaVac recipients	13
Global prevalence of depression and anxiety in patients with hepatocellular carcinoma: Systematic review and meta-analysis	13
Hepatocellular carcinoma surveillance in patients with non-alcoholic fatty liver disease	13
Hepatitis B core-related antigen: A novel and promising surrogate biomarker to guide anti-hepatitis B virus therapy	13
Clinical practice guideline and real-life practice in hepatocellular carcinoma: A Korean perspective	13
Cost-effectiveness of chronic hepatitis C screening and treatment	13
Hepatocytes infected with hepatitis C virus change immunological features in the liver microenvironment	13
Pharmacological advances in the treatment of nonalcoholic fatty liver diseases : focused on global results of randomized controlled trials	13
The cut-off value of transient elastography to the value of hepatic venous pressure gradient in alcoholic cirrhosis	12
Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future	12
Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Taiwan perspective	12
Current knowledge about biomarkers of acute kidney injury in liver cirrhosis	12
Non-alcoholic fatty liver disease: the pathologist’s perspective	12
Hepatitis B virus pre-genomic RNA and hepatitis B core-related antigen reductions at week 4 predict favourable hepatitis B surface antigen response upon long-term nucleos(t)ide analogue in chronic hep	12
Taurocholic acid promotes hepatic stellate cell activation via S1PR2/p38 MAPK/YAP signaling under cholestatic conditions	12
Deep learning-based prediction of molecular cancer biomarkers from tissue slides: A new tool for precision oncology	12
Comedications and potential drug-drug interactions with direct-acting antivirals in hepatitis C patients on hemodialysis	12
Direct comparison of biopsy techniques for hepatic malignancies	11
The role of different viral biomarkers on the management of chronic hepatitis B	11
Statin and aspirin for chemoprevention of hepatocellular carcinoma: Time to use or wait further?	11
Recent advances in the management of hepatocellular carcinoma	11
Current status and outcome of liver transplantation in South Korea	11
The impact of unrestricted access to direct-acting antiviral among incarcerated hepatitis C virus-infected patients	10
Nonalcoholic fatty liver disease and early prediction of gestational diabetes mellitus using machine learning methods	10
Association between new-onset liver cirrhosis and suicide risk in South Korea: A nationwide cohort study	10
Identification of high-risk subjects in nonalcoholic fatty liver disease	10
Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis	10
Clinical practice guidelines and real-life practice on hepatocellular carcinoma: the Hong Kong perspective	10
Non-invasive biomarkers for liver inflammation in non-alcoholic fatty liver disease: present and future	10
Effects of interleukin-17 inhibitors on hepatic fibrosis index in patients with psoriasis and metabolic dysfunction-associated fatty liver disease: Directed acyclic graphs	10
Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity	10